Search

Displaying results 131 - 140 of 3750 in total
  1. Drug

    Methotrexate

    go.drugbank.com/drugs/DB00563
    ApprovedInvestigational

    Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate i...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: EMTHEXATE PF, EMTHEXATE PF 25 MG/ML
  2. Drug

    Alfacalcidol

    go.drugbank.com/drugs/DB01436
    ApprovedInvestigationalNutraceutical

    Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of vitamin D. It plays an essential function in calcium homeostasis and bone metabolism. Alfacaldisol is activated by the enzyme 2...

    Products: PP Alfa-DOL 1.00 mcg Capsule
  3. Drug

    Becotatug

    go.drugbank.com/drugs/DB19069
    Investigational

    JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor

    Synonyms: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr)), Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-Mus musculus monoclonal JMT101 γ1-chain), disulfide with human-Mus musculus monoclonal JMT101 κ-chain, dimer
  4. Drug

    Formoterol

    go.drugbank.com/drugs/DB00983
    ApprovedInvestigational

    [A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration

    Mixtures: SYMBICORT PI 80/4.5UG120ED, SYMBICORT PI 80/4.5UG120EDCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  5. Pathway

    Sphingolipid Signaling (Receptor)

    smpdb.ca/view/SMP0524344
    Signaling

    Through these receptor‑specific G protein couplings—spanning cAMP suppression, Ca²⁺ mobilization, PKC activation, Rho GTPase–driven cytoskeletal remodeling, and PI3K/Akt and MAPK pathways—S1P orchestrates

    Drugs: Nitric oxide · Calcium · Magnesium cation
    Enzymes: Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 4
  6. Drug

    PBCAR20A

    go.drugbank.com/drugs/DB17189
    Investigational

    Synonyms: Allogeneic gene edited CD20-directed CAR (Chimeric Antigen Receptor) T cells
  7. Drug

    Tenofovir disoproxil

    go.drugbank.com/drugs/DB00300
    ApprovedInvestigational

    Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug ...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: TENOFOVIRDISOPROXIL PU 245
  8. Drug

    EDI-200

    go.drugbank.com/drugs/DB18188
    Investigational

    EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.

    Synonyms: HUMAN IMMUNOGLOBULIN G1 CONSTANT REGION - HUMAN ECTODYSPLASIN-A1 RECEPTOR-BINDING DOMAIN FUSION PROTEIN
  9. Drug

    Recombinant human alkaline phosphatase

    go.drugbank.com/drugs/DB17672
    Investigational

    Synonyms: recAP
  10. Drug

    Rivastigmine

    go.drugbank.com/drugs/DB00989
    ApprovedInvestigational

    Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

    Products: RIVASTIGMIN 1A PH 3MG HART, RIVASTIGMIN 1A PH 6MG HART